REFRACTORY PRIMARY CNS LYMPHOMA

Clinical trials for REFRACTORY PRIMARY CNS LYMPHOMA explained in plain language.

Never miss a new study

Get alerted when new REFRACTORY PRIMARY CNS LYMPHOMA trials appear

Sign up with your email to follow new studies for REFRACTORY PRIMARY CNS LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Reprogrammed immune cells take aim at deadly brain cancer

Disease control Completed

This early-stage study tested the safety of a personalized cell therapy called tisagenlecleucel in patients with primary central nervous system lymphoma, a rare and aggressive cancer of the brain. The therapy involves collecting a patient's own immune cells, modifying them in a l…

Matched conditions: REFRACTORY PRIMARY CNS LYMPHOMA

Phase: PHASE1 • Sponsor: Matthew J. Frigault, M.D. • Aim: Disease control

Last updated Mar 10, 2026 12:52 UTC

REFRACTORY PRIMARY CNS LYMPHOMA

Get alerted when new REFRACTORY PRIMARY CNS LYMPHOMA trials appear

Reprogrammed immune cells take aim at deadly brain cancer